Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial

United European Gastroenterology Journal

Volumn 6, Issue 1, 2018, Pages 138-147

  Dignass, Axel ^a   Schnabel, Robert ^b   Romatowski, Jacek ^c   Pavlenko, Vladimir ^d   Dorofeyev, Andrey ^e   Derova, Jelena ^f   Jonaitis, Laimas ^g   Dilger, Karin ^h   Nacak, Tanju ⁱ   Greinwald, Roland ⁱ  

^a AGAPLESION MARKUS KRANKENHAUS   (Germany)

^b Pannónia Magánorvosi Centrum Kft   (Hungary)

^c Gastromed sc   (Poland)

^d E A VAGNER PERM STATE MEDICAL UNIVERSITY   (Russian Federation)

^e DONETSK MEDICAL UNIVERSITY   (Ukraine)

^f Latvian Maritime Medical Centre   (Latvia)

^g LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^h Dr Falk Pharma GmbH   (Germany)

ⁱ Dr Falk Pharma GmbH   (Germany)

Author keywords

adherence; efficacy; Mesalazine; randomised; ulcerative colitis

Indexed keywords

MESALAZINE; PLACEBO;

ADULT; AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PREFERENCE; DRUG SAFETY; FEMALE; HEALING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; TABLET; ULCERATIVE COLITIS;

EID: 85041124807     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640617703842     Document Type: Article

References (31)

1. Cohen RD, Woseth DM, Thisted RA, A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000; 95: 1263–1276.
2. Gibson PR, Vaizey C, Black CM, Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis 2014; 8: 598–606.
3. Theede K, Kiszka-Kanowitz M, Nordgaard-Lassen I, The impact of endoscopic inflammation and mucosal healing on health-related quality of life in ulcerative colitis patients. J Crohns Colitis 2015; 9: 625–632.
4. Dignass A, Lindsay JO, Sturm A, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management. J Crohns Colitis 2012; 6: 991–1030.
5. Feagan BG, Macdonald JK. Oral 5-aminosalicyclic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000543–CD000543.
6. Wang Y, Parker CE, Bhanji T, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 4: CD000543–CD000543.
7. Lachaine J, Yen L, Beauchemin C, Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol 2013; 13: 23–23.
8. Lakatos PL, Czegledi Z, David G, Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis 2010; 4: 283–290.
9. Loftus EV, Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12: 1107–1113.
10. Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther 2009; 29: 1114–1120.
11. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82–86.
12. Riley SA, Mani V, Goodman MJ, Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174–178.
13. Hjortswang H, Jarnerot G, Curman B, The Short Health Scale: a valid measure of subjective health in ulcerative colitis. Scand J Gastroenterol 2006; 41: 1196–1203.
14. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 45: 353–365.
15. Gross V, Bunganic I, Belousova EA, International BUC-57 Study Group. 3 g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2011; 5: 129–138.
16. Leifeld L, Pfutzer R, Morgenstern J, Mesalazine granules are superior to Eudragit-l-coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis. Aliment Pharmacol Ther 2011; 34: 1115–1122.
17. Su C, Lewis JD, Goldberg B, A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516–526.
18. D’Haens G, Sandborn WJ, Feagan BG, A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763–786.
19. Gross V, Bar-Meir S, Lavy A, International Budesonide Foam Study Group. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006; 23: 303–312.
20. Kruis W, Bar-Meir S, Feher J, The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 36–43.
21. Hartmann F, Stein J. BudMesa-Study Group. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. Aliment Pharmacol Ther 2010; 32: 368–376.
22. Eliakim R, Tulassay Z, Kupcinskas L, International Salofalk Foam Study Group. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 1237–1249.
23. Hoivik ML, Moum B, Solberg IC, IBSEN Study Group. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis 2012; 18: 1540–1549.
24. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 10: CD000544–CD000544.
25. Marakhouski Y, Fixa B, Holomán J, International Salofalk Study Group. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 133–140.
26. Kruis W, Jonaitis L, Pokrotnieks J, International Salofalk OD Study Group. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313–322.
27. Kane SV, Cohen RD, Aikens JE, Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929–2933.
28. Kane S, Huo D, Aikens J, Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39–43.
29. Kane SV. Strategies to improve adherence and outcomes in patients with ulcerative colitis. Drugs 2008; 68: 2601–2609.
30. Kamm MA, Lichtenstein GR, Sandborn S, Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893–902.
31. Flourié B, Hagège H, Tucat G, MOTUS study investigators. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther 2013; 37: 767–775.